Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Partially Blinded, Randomized, Controlled, Parallel-Group, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact in Preterm Infants at Risk of Worsening Respiratory Distress Syndrome

NCT03969992 is registered in ClinicalTrials.gov with Aerogen Pharma Limited as lead sponsor.

NCT NCT03969992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03969992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Partially Blinded, Randomized, Controlled, Parallel-Group, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact in Preterm Infants at Risk of Worsening Respiratory Distress Syndrome
Lead sponsor
Aerogen Pharma Limited
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2020
Completion date
August 5, 2024
Enrollment
261 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory distress syndrome in premature infant